[1] [1] ANFOSSI S, FU X, NAGVEKAR R, et al. MicroRNAs, regula- tory messengers inside and outside cancer cells［J］. Advances in Experimental Medicine and Biology, 2018, 1056: 87-108.

[2] [2] XING Y, WANG Z, LU Z, et al. MicroRNAs: immune modulators in cancer immunotherapy［J］. Immunotherapy Advances, 2021, 1( 1): ltab006.

[3] [3] REBECCA V W, SOMASUNDARAM R, HERLYN M, et al. Pre- clinical modeling of cutaneous melanoma［J］. Nature Communi- cations, 2020, 11( 1): 2858.

[4] [4] SHI Xingdan,WU Jin. Differential expression and clinical signifi- cance of miRNA in malignant melanoma［J］. Modern Oncology, 2020, 28(24): 4375-4378.

[5] [5] CHEN Q, CHEN S, ZHAO J, et al. MicroRNA-126: a new and promising player in lung cancer［J］. Oncology Letters, 2021, 21( 1): 35.

[6] [6] SOOFIYANI S R, HOSSEINI K, EBRAHIMI T, et al. Prognostic value and biological role of mir-126 in breast cancer［J］. Micror- na, 2022, 11(2): 95-103.

[7] [7] WANG Shuxian, WANG Fangfang. Research progress on the relation- ship between micromolecular RNA and chronic myeloid leukemia［J］. Journal ofGraduate Medical Sciences, 2020, 33(2): 188-191.

[8] [8] LIN N, ZHOU Y, LIAN X, et al. Down-regulation of tissue mi- croRNA-126 was associated with poor prognosis in patients with cutaneous melanoma［J］. International Journal of Clinical and Experimental Medicine, 2015, 8(3): 4297-4301.

[9] [9] SU T, WANG Y P, WANG X N, et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of brevilin A［J］. Life Sciences, 2020, 241: 117169.

[10] [10] WU K J, HUANG J M, ZHONG H J, et al. A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells［J］. PLoS One, 2017, 12(6): e0177123.

[11] [11] XU J, WANG H, WANG H, et al. The inhibition of miR-126 in cell migration and invasion of cervical cancer through regulating ZEB1［J］. Hereditas, 2019, 156: 11.

[12] [12] ZHOU Xiaocheng. Molecular mechanism of exosome-mediated angiogenesis-promoting transformation of melanoma-associated fibroblasts［D］. Wuhan: Wuhan University, 2019.

[13] [13] HAO Yuzhi, CAI Xiao, JIN Yifeng, et al. Investigation of the mechanism of osteopontine in alleviating inflammatory response after cerebral hemorrhage in hyperglycemic rats based on JAK2/ STAT1 signaling pathway［J］. Stroke and Neurological Diseases, 2021, 28(6): 622-630.

[14] [14] FOCHI S, ORLANDI E, CECCUZZI L, et al. Identification of suitable mRNAs and microRNAs as reference genes for expression analyses in skin cells under sex hormone exposure［J］. Gene, 2021, 769: 145336.

[15] [15] CAPORALI S, AMARO A, LEVATI L, et al. miR-126-3p down- regulation contributes to dabrafenib acquired resistance in mela- noma by up-regulating ADAM9 and VEGF-A［J］. Journal of Experimental & Clinical Cancer Research, 2019, 38( 1): 272.

[16] [16] LU W, TAO X, FAN Y, et al. LINC00888 promoted tumorigenic- ity of melanoma via miR-126/CRK signaling axis［J］. OncoTar- gets and Therapy, 2018, 11: 4431-4442.

[17] [17] PEDINI F, DE LUCA G, FELICETTI F, et al. Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma ［J］. Molecular Oncology, 2019, 13(9): 1836-1854.

[18] [18] FU X Q, CHOU J Y, LI T, et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I［J］. Ex- perimental Dermatology, 2018, 27(2): 201-204.

[19] [19] MITTAL V. Epithelial mesenchymal transition in tumor metastasis ［J］. Annual Review of Pathology, 2018, 13: 395-412.

[20] [20] WEISS F, LAUFFENBURGER D, FRIEDL P, et al. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance［J］. Nature Reviews Cancer, 2022, 22(3): 157-173.

[21] [21] GANJU A, KHAN S, HAFEEZ B B, et al. miRNA nanotherapeu- tics for cancer［J］. Drug Discovery Today, 2017, 22(2): 424-432.

[22] [22] YANG C, WANG R, HARDY P, et al. Potential of miRNA-based nanotherapeutics for uveal melanoma［J］. Cancers (Basel), 2021, 13(20): 5192.